喀麦隆病毒血症可检测青少年中HIV-1耐药突变的高水平存档与循环
本研究对90名病毒载量≥200拷贝/mL的10-19岁青少年,利用127份血浆和配对血沉棕黄层样本,同时检测循环和存档病毒的逆转录酶、蛋白酶和整合酶基因耐药突变。结果显示约80%参与者至少对一类药物存在耐药突变,且循环与存档病毒耐药谱存在差异,提示需同时评估两种病毒群体。
要点
- 约80%病毒血症可检测青少年至少对一类药物耐药,主要为NRTI和NNRTI相关。
- 三分之一参与者对新型NNRTI(利匹韦林、多拉韦林)交叉耐药。
- 循环病毒中独有耐药突变是存档病毒的2倍,提示需同时检测两者。
核心结论
- 在病毒血症可检测的喀麦隆青少年中,循环和存档病毒均呈现高水平HIV-1耐药突变。
- 同时评估两种病毒群体的耐药谱可提供额外信息。
研究设计与样本
- 研究纳入90名10-19岁病毒载量≥200拷贝/mL的青少年,采集127份血浆和配对血沉棕黄层样本(2021年2月至9月)。
- 采用in-house Sanger法对循环和存档病毒株的逆转录酶、蛋白酶和整合酶基因进行耐药基因型检测。
- 使用Stanford HIValg程序识别相关耐药突变。
主要发现
- 获得97对(76.4%)配对存档和循环病毒序列,其中60对(61.9%)为重组型CRF02_AG。
- 循环病毒中80.4%、存档病毒中77.3%的参与者至少对一类药物存在耐药突变,在病毒载量200-999拷贝/mL样本中略高,主要为NRTI和NNRTI相关耐药。
- 三分之一参与者对利匹韦林和多拉韦林存在交叉耐药。
- 56.7%的耐药突变在两种病毒群体中均检测到,但循环病毒中独有突变是存档病毒的2倍(29.8% vs 13.4%)。
临床怎么用
- 对病毒血症可检测的青少年进行耐药检测时,应同时评估循环和存档病毒以全面了解耐药谱。
- 需关注对新型NNRTI的交叉耐药,即使这些药物在当地尚未上市。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We previously reported a high prevalence of HIV drug resistance mutations (DRMs) among adolescents with a viral load (VL) ≥ 200 copies/mL. In this study, we complement this analysis by simultaneously characterizing circulating and archived viruses in order to obtain a more comprehensive drug resistance profile. METHODS: Using 127 plasma and paired buffy-coat samples collected between February and September 2021 from 90 adolescents (10-19 years) with a VL ≥ 200 copies/mL, we performed genotyping resistance testing on both circulating and archived viral strains using an in-house Sanger method targeting the reverse transcriptase, protease and integrase genes. The Stanford HIValg programme was used to identify relevant DRMs. RESULTS: We generated 97 (76.4%) paired archived and circulating viral sequences, of which 60 (61.9%) were recombinant CRF02_AG. Globally, about 8/10 participants harboured DRMs to at least one drug class in circulant (80.4%) and archived (77.3%) viruses, slightly higher in samples with VL between 200 and 999 copies/mL and mainly NRTIs and NNRTI-associated resistance. One-third of the participants had cross-resistance to the newer NNRTIs rilpivirine and doravirine, which are not yet available in our settings. More than half (56.7%) of the DRMs were detected in both viral populations, but 2-fold more DRMs were found exclusively in circulant strains (29.8% versus 13.4% in archived viruses). CONCLUSION: The high level of resistance found in this study, coupled with the identification of DRMs either in circulating and archived viruses, only suggests that a comprehensive profiling of DRMs in both viral populations would provide additional information for adolescents with a detectable viremia.
引用
- Djiyou ABD, Penda CI, Madec Y, et al. High level of archived and circulating HIV-1 drug resistance mutations in adolescents with a detectable viremia in Cameroon. J Antimicrob Chemother. 2025. PMID: 41047881. doi:10.1093/jac/dkaf356
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。